Liver transplantation for patients with metastatic endocrine tumors: Single-center experience with 15 patients

Liver Transplantation

Volumn 12, Issue 7, 2006, Pages 1089-1096

  Frilling, Andrea ^a   Malago, Massimo ^a   Weber, Frank ^a   Paul, Andreas ^a   Nadalin, Silvio ^a   Sotiropoulos, Georgios C ^a   Cicinnati, Vito ^a   Beckebaum, Susanne ^a   Bockisch, Andreas ^a   Mueller Brand, Jan ^b   Hofmann, Michael ^c   Schmid, Kurt W ^a   Gerken, Guido ^a   Broelsch, Christoph E ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALPHA INTERFERON; CORTICOSTEROID; CYCLOSPORIN; GALLIUM 68; KI 67 ANTIGEN; LUTETIUM 177; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; RAPAMYCIN; SOMATOSTATIN RECEPTOR; TACROLIMUS; YTTRIUM 90;

ADULT; AGED; ARTICLE; CADAVER DONOR; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOID; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ENDOCRINE TUMOR; EXPERIENCE; FEMALE; FOLLOW UP; GASTRECTOMY; GRAFT VERSUS HOST REACTION; HOSPITAL DISCHARGE; HUMAN; ILEUM RESECTION; INTESTINE CANCER; LIVER METASTASIS; LIVER SCINTISCANNING; LIVER TRANSPLANTATION; LIVING DONOR; LUNG CANCER; LUNG LOBECTOMY; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SPLENECTOMY; SURGICAL APPROACH; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL RATE;

EID: 33745987328     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20755     Document Type: Article

References (37)

1. Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 1988;104:1011-1017.
2. Matthews B, Heniford B, Reardon P, Brunicardi F, Greene F. Surgical experience with non-functioning neuroendocrine tumors of the pancreas. Am Surg 2000;66:1116-1123.
3. Chu QD, Hill HC, Douglass HO Jr, Driscoll D, Smith JL, Nava HR, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002;9:855-862.
4. Jensen RT. Natural history of digestive endocrine tumors. In: Mignon M, Colombel JF, eds. Recent advances in pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors. Paris: John Libbey Eurotext Publishing Co; 1999:192-219.
5. Sutliff VE, Doppman JL, Gibril F, Venzon DJ, Yu F, Serrano J, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth pattern. J Clin Oncol 1997;15:2420-2431.
6. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y. Metastatic endocrine tumors: medical treatment surgical resection, or liver transplantation. World J Surg 1996;20:908-915.
7. Johanson V, Tisell LE, Olbe L, Wangberg B, Nilsson O, Ahlman H. Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin. Br J Cancer 1999;89:1259-1261.
8. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000;62(suppl):51-58.
9. Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg 1995;19:76-82.
10. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991;110:726-735.
11. Curtiss SI, Mor E, Schwartz ME, Sung MW, Hytiroglou P, Thung SN, et al. A rational approach to the use of hepatic transplantation in the treatment of metastatic neuroendocrine tumors. J Am Coll Surg 1995;180:184-187.
12. Routley D, Ramage JK, McPeake J, Than K-C, Williams R. Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver. Liver Trans Surg 1995;1:118-121.
13. Lang H, Oldhafer KJ, Weimann A, Schlitt HJ, Scheumann GFW, Flemming P, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225:347-354.
14. Olausson M, Friman S, Cahlin C, Nilsson O, Jansson S, Wängberg B, et al. Indications and results of liver transplantation in patients with neuroendocrine tumors. World J Surg 2002;26:998-1004.
15. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004;8:208-212.
16. Frilling A, Rogiers X, Malago M, Liedke O, Kaun M, Broelsch CE. Liver transplantation in patients with liver metastases of neuroendocrine tumors. Transpl Proc 1998;30: 3298-3300.
17. Frilling A, Rogiers X, Malago M, Liedke OM, Kaun M, Broelsch CE. Treatment of liver metastases in patients with neuroendocrine tumors. Langenbecks Arch Surg 1998;383:62-70.
18. Malago M, Testa G, Frilling A, Nadalin S, Valentin-Gamazo C, Paul A, et al. Right living donor liver transplantation: an option for adult patients. Single institution experience with 74 patients. Ann Surg 2003;238:853-863.
19. Makowka L, Tzakis AG, Mazzaferro V, Teperman L, Demetris AJ, Iwatsuki S, et al. Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. Surg Gynecol Obstet 1989;168:107-111.
20. Arnold JC, O'Grady JG, Bird GL, Calne RY, Williams R. Liver transplantation for primary and secondary hepatic apudomas. Br J Surg 1989;76:248-249.
21. Ringe B, Wittekind C, Bechstein WO, Bunzendahl H, Pichlmayr R. The role of liver transplantation in hepatobiliary malignancy. A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann Surg 1989;209:88-98.
22. Bechstein WO, Neuhaus P. Liver transplantation for hepatic metastases of neuroendocrine tumors. Ann N Y Acad Sci 1994;733:507-514.
23. Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. Ann Surg 1997;225:355-364.
24. Knechtle SJ, Kalayoglu M, D'Alessandro AM, Rikkers LF. Proceed with caution: liver transplantation for metastatic neuroendocrine tumors [editorial]. Ann Surg 1997;225: 345-346.
25. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68Ga)-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751-1757.
26. Amarapurkar AD, Davies A, Ramage JK, Stangou AJ, Wight DGD, Portmann BC. Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis. Eur J Gastroenterol Hepatol 2003;15:139-143.
27. Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002;73:386-394.
28. Pascher A, Steinmüller T, Radke C, Hosten N, Wiedenmann B, Neuhaus P, et al. Primary and secondary hepatic manifestation of neuroendocrine tumors. Langenbecks Arch Surg 2000;385:265-270.
29. Gulanikar AC, Kotylak G, Bitter-Suermann H. Does immunosuppression alter the growth of metastatic liver carcinoid after orthotopic liver transplantation? Transplant Proc 1991;23:2197-2198.
30. 3] octreotate. Eur J Nucl Med 2003;30:417-422.
31. 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 2004; 136:1218-1226.
32. 11In-pentetretide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003; 44:1-6.
33. Gondolesi GE, Roayaie S, Munoz L, Kim-Schluger L, Schiano T, Fishbein TM, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: Extending UNOS priority criteria. Ann Surg 2004; 239:142-149.
34. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-135.
35. Sotiropoulos GC, Paul A, Molmenti E, Lang H, Frilling A, Napieralski B, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis within the Eurotransplant area: an additional option with "livers that nobody wants." Transplantation 2005;80:897-902.
36. Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10:1301-1311.
37. Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-Green G, et al. A retrospective review of liver transplant patients treated with strolimus from a single center: an analysis of sirolimus related complications. Transplantation 2004;78:264-268.